The Assessment of short-term effect of L-Citrulline on endothelial function via FMD to NMD ratio in known CAD patients: A randomized, cross-over clinical trial (Clinical trial number: NCT02638727)

Open access

Abstract

Background. Recent studies have confirmed the essential and paramount role of the L-Citrulline on the nitric oxide regulation and the endothelial function improvement.

Materials and Methods. In this cross-over clinical trial, thirty patients, diagnosed with coronary artery disease (CAD) and flow mediated dilation to nitroglycerin dependent vasodilation (FMD/NMD) ratio less than 1, were included. The patients were randomly divided into two groups of 15 patients and underwent treatment by L-Citrulline or placebo for 15 days, in 2 step protocol. The indicators of assessment in the current study were the ratio of the FMD/NMD and FMD value.

Results. In the current cross-over clinical trial, the mean of FMD to NMD ratio and mean FMD value of all patients before starting the protocol were 0.91 ± 0.08 and 4.04 ± 0.51 mm, respectively. The final results of study showed that following L-Citrulline administration, mean FMD to NMD ratio and mean FMD value were enhanced to: 1.03 ± 0.09 and 4.96 ± 0.72 mm, respectively, which were statistically significant (P<0.001 and P<0.001, respectively). However, following placebo administration, mean FMD to NMD ratio and mean FMD value were receded to: 0.92 ± 0.09 and 4.06 ± 0.22 mm, respectively, which were not statistically significant (P = 0.75 and P = 0.89, respectively). Moreover, the improvement of mean FMD to NMD ratio (0.12 ± 0.02) and mean FMD value (0.92 ± 0.16 mm), following L-Citrulline administration, were statistically significant in comparison with the change of mean FMD to NMD ratio (0.01 ± 0.002) and mean FMD value (0.02 ± 0.003), following placebo administration (P<0.001 and P<0.001, respectively).

Conclusion. L-Citrulline treatment can lead to improvement of the endothelial function in patients diagnosed with CAD which are assessed via FMD to NMD ratio FMD value enhancements.

1. ABOU-MOHAMED G., JOHNSON JA., JIN L., EL-REMESSY AB., DO K., KAESEMEYER WH., et al. Roles of superoxide, peroxynitrite, and protein kinase C in the development of tolerance to nitroglycerin. J Pharmacol Exp Ther. 2004; 308 (1):289-99.

2. ASAGA H., ISHIGAMI A. Protein deimination in the rat brain after kainate administration: citrulline-containing proteins as a novel marker of neurodegeneration. Neurosci Lett. 2001; 299 (1-2):5-8.

3. BAYDOUN AR., BOGLE RG., PEARSON JD., MANN GE. Discrimination between citrulline and arginine transport in activated murine macrophages: inefficient synthesis of NO from recycling of citrulline to arginine. Br J Pharmacol. 1994; 112 (2):487-92.

4. BERKOWITZ DE., WHITE R., LI D., MINHAS KM., CERNETICH A., KIM S., et al. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation. 2003; 108 (16):2000-6.

5. DILLON EL., KNABE DA., WU G. Lactate inhibits citrulline and arginine synthesis from proline in pig enterocytes. Am J Physiol. 1999; 276 (5 Pt 1):G1079-86.

6. DONG S., KOJIMA T., SHIRAIWA M., MECHIN MC., CHAVANAS S., SERRE G., et al. Regulation of the expression of peptidylarginine deiminase type II gene (PADI2) in human keratinocytes involves Sp1 and Sp3 transcription factors. J Invest Dermatol. 2005; 124 (5):1026-33.

7. INOUE Y., COPELAND EM., SOUBA WW. Growth hormone enhances amino acid uptake by the human small intestine. Ann Surg. 1994; 219 (6):715-22; discussion 22-4.

8. ISHIGAMI A., OHSAWA T., ASAGA H., AKIYAMA K., KURAMOTO M., MARUYAMA N. Human peptidylarginine deiminase type II: molecular cloning, gene organization, and expression in human skin. Arch Biochem Biophys. 2002; 407 (1):25-31.

9. CREAGER MA., COOKE JP., MENDELSOHN ME., GALLAGHER SJ., COLEMAN SM., LOSCALZO J., et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest. 1990; 86 (1):228-34.

10. CURIS E., NICOLIS I., MOINARD C., OSOWSKA S., ZERROUK N., BENAZETH S., et al. Almost all about citrulline in mammals. Amino Acids. 2005; 29 (3):177-205.

11. JEAN C., ROME S., MATHE V., HUNEAU JF., AATTOURI N., FROMENTIN G., et al. Metabolic evidence for adaptation to a high protein diet in rats. J Nutr. 2001; 131 (1):91-8.

12. JEREMY RW., MCCARRON H., SULLIVAN D. Effects of dietary L-arginine on atherosclerosis and endothelium-dependent vasodilatation in the hypercholesterolemic rabbit. Response according to treatment duration, anatomic site, and sex. Circulation. 1996; 94 (3):498-506.

13. SANCHEZ-GONZALEZ MA., KOUTNIK AP., RAMIREZ K., WONG A., FIGUEROA A. The effects of short term L-citrulline supplementation on wave reflection responses to cold exposure with concurrent isometric exercise. Am J Hypertens. 2013; 26 (4):518-26.

14. OREA-TEJEDA A., OROZCO-GUTIERREZ JJ., CASTILLO-MARTINEZ L., KEIRNS-DAVIES C., MONTANOHERNANDEZ P., VAZQUEZ-DIAZ O., et al. The effect of L-arginine and citrulline on endothelial function in patients in heart failure with preserved ejection fraction. Cardiol J. 2010; 17 (5):464-70.

15. BALDERAS-MUNOZ K., CASTILLO-MARTINEZ L., OREA-TEJEDA A., INFANTE-VAZQUEZ O., UTRERA-LAGUNAS M., MARTINEZ-MEMIJE R., et al. Improvement of ventricular function in systolic heart failure patients with oral L-citrulline supplementation. Cardiol J. 2012; 19 (6):612-7.

16. IKEDA Y., YOUNG LH., SCALIA R., LEFER AM. Cardioprotective effects of citrulline in ischemia/reperfusion injury via a non-nitric oxide-mediated mechanism. Methods Find Exp Clin Pharmacol. 2000; 22 (7):563-71.

17. OROZCO-GUTIERREZ JJ., CASTILLO-MARTINEZ L., OREA-TEJEDA A., VAZQUEZ-DIAZ O., VALDESPINO-TREJO A., NARVAEZ-DAVID R., et al. Effect of L-arginine or L-citrulline oral supplementation on blood pressure and right ventricular function in heart failure patients with preserved ejection fraction. Cardiol J. 2010; 17 (6):612-8.

Journal Information

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 103 103 15
PDF Downloads 51 51 9